Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.57 |
| ▸ | FDPS | P14324 | 1/20 | 0.49 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7992010 | 0.94 | ALDH1A1 (0.56) | ALDH1A1MAPTHPGDSMN1; SMN2LMNA | |
| SCHEMBL3210160 | 0.94 | ALDH1A1 (0.56) | ALDH1A1MAPTHPGDSMN1; SMN2LMNA | |
| SCHEMBL3211688 | 0.94 | ALDH1A1 (0.56) | ALDH1A1MAPTHPGDSMN1; SMN2LMNA | |
| SCHEMBL7989945 | 0.90 | ALDH1A1 (0.64) | ALDH1A1MAPTHPGDSMN1; SMN2LMNA | |
| SCHEMBL3720061 | 0.90 | ALDH1A1 (0.69) | ALDH1A1MAPTHPGDSMN1; SMN2LMNA | |
| SCHEMBL851166 | 0.89 | ALDH1A1 (0.66) | ALDH1A1MAPTHPGDSMN1; SMN2LMNA | |
| SCHEMBL27256901 | 0.89 | ALDH1A1 (0.62) | ALDH1A1MAPTHPGDSMN1; SMN2LMNA | |
| SCHEMBL19214413 | 0.88 | ALDH1A1 (0.76) | ALDH1A1MAPTHPGDSMN1; SMN2LMNA | |
| SCHEMBL1524953 | 0.87 | ALDH1A1 (0.52) | ALDH1A1MAPTHPGDSMN1; SMN2LMNA | |
| SCHEMBL18477951 | 0.84 | ALDH1A1 (0.66) | ALDH1A1MAPTHPGDSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102887862-A | Method for synthesizing erlotinib | LIANYUNGANG SHENGHE BIOTECHNOLOGY CO LTD | 2013-01-23 | — | — | CN | claimed |
| US-20250170112-A1 | ADENOSINE LIGANDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | LUCY THERAPEUTICS, INC. | 2025-05-29 | — | — | US | disclosed |
| EP-4069366-B1 | ATM KINASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION INC (US) | 2025-03-19 | — | — | EP | disclosed |
| WO-2025038783-A1 | ADENOSINE LIGANDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS OR CHRONIC HEART FAILURE | LUCY THERAPEUTICS, INC. (US) | 2025-02-20 | — | — | WO | disclosed |
| WO-2025038781-A1 | ADENOSINE LIGANDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS OR CHRONIC HEART FAILURE | LUCY THERAPEUTICS, INC. (US) | 2025-02-20 | — | — | WO | disclosed |
| US-20250026749-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2025-01-23 | — | — | US | disclosed |
| EP-4479399-A1 | ADENOSINE LIGANDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Lucy Therapeutics, Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| CN-118546167-A | Near infrared fluorescent dye and fluorescent composite material | 复旦大学 | 2024-08-27 | — | — | CN | disclosed |
| US-12060349-B2 | Glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2024-08-13 | — | — | US | disclosed |
| WO-2023158725-A1 | ADENOSINE LIGANDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | LUCY THERAPEUTICS, INC. (US) | 2023-08-24 | — | — | WO | disclosed |
| US-6288061-B1 | INTERLEUKIN INHIBITORS; ASTHMA, BRONCHODILATOR AGENTS, ANTIALLERGENS | WELFIDE CORPORATION (JP) | 2001-09-11 | — | — | US | disclosed |
| US-20010014697-A1 | Process for the preparation of 2-methoxyethoxy-benzenes and novel 2-methoxyethoxy-benzyl cyanides | LANXESS DEUTSCHLAND GMBH (DE) | 2001-08-16 | — | — | US | disclosed |
| EP-1123913-A2 | Process for preparing 2-methoxyethoxybenzenes and new 2-methoxyethoxybenzyl cyanides | BAYER AG (DE) | 2001-08-16 | — | — | EP | disclosed |
| US-5840902-A | REACTING PICOLINE WITH ALKYLENE OXIDE IN PRESENCE OF ACID IN WATER OR MIXTURE OF WATER AND POLAR SOLVENT | BAYER AKTIENGESELLSCHAFT (DE) | 1998-11-24 | — | — | US | disclosed |
| EP-0776888-A2 | Process for the preparation of beta-Hydrosyalkylpicolinium salts and picolinium salts as intermediates for the prepation of cationic dyes | BAYER AG (DE) | 1997-06-04 | — | — | EP | disclosed |
| US-5422367-A | A hormon inhibitors and for inhibiting the development of an estrogen-dependent tumor | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1995-06-06 | — | — | US | disclosed |
| US-5324736-A | Diphenylcyclopropyl analogs as antiestrogenic and antitumor agents | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1994-06-28 | — | — | US | disclosed |
| US-5098903-A | Halocyclopropanes | BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 1992-03-24 | — | — | US | disclosed |
| US-4009208-A | N,N'-HEPTAMETHYLENEBIS(4-METHOXYBENZAMIDE) | STERLING DRUG INC. (US) | 1977-02-22 | — | — | US | disclosed |
| US-3962219-A | DISTYRYL-BENZOBISOXAZOLES | BAYER AKTIENGESELLSCHAFT (DT) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12060349-B2 | Glucosylceramide synthase inhibitors | GBA1, GBA2, GALC | ALDH1A1 2066/4885MAPT 3852/4885HPGD 1298/4885 |
| US-20250026749-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | ALDH1A1 2144/4885MAPT 4277/4885HPGD 1041/4885 |
| US-20250170112-A1 | ADENOSINE LIGANDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | ADORA2A, ADORA1, PDE7A | ALDH1A1 1355/4885MAPT 154/4885HPGD 1722/4885 |
| US-20010014697-A1 | Process for the preparation of 2-methoxyethoxy-benzenes and novel 2-methoxyethoxy-benzyl cyanides | TET2, CYCS, TYR | ALDH1A1 4144/4885MAPT 3465/4885HPGD 992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.